Overview

A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

This is a phase trial to determine the maximum tolerated dose (MTD) of clofarabine in a combination with a myeloablative dose of busulfan. This is an initial step in developing a novel myeloablative preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT). While this phase I trial will initially develop the regimen in patients with refractory disease, it is expected that it will find its best application in patients with less advanced disease

Phase:

Phase 1

Details

Lead Sponsor:

Indiana University School of Medicine

Collaborator:

Genzyme, a Sanofi Company

Treatments:

Busulfan
Clofarabine